The effects of the COVID-19 pandemic on hallucinations and delusions in youth at clinical high-risk for psychosis and outpatients with schizophrenia.

"Declarations Conflicts of interestGS is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. GS has received honoraria and travel support from ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past three years, GS has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Boehringer Ingelheim, Acadia, Otsuka, Sunovion, and Lundbeck pharmaceutical companies. All other authors have no conflicts to report. Conflicts of interest GS is one of the original developers of the Brief Negative Symptom Scale (BNSS) and receives royalties and consultation fees from ProPhase LLC in connection with commercial use of the BNSS and other professional activities; these fees are donated to the Brain and Behavior Research Foundation. GS has received honoraria and travel support from ProPhase LLC for training pharmaceutical company raters on the BNSS. In the past three years, GS has consulted for and/or been on the speaker bureau for Minerva Neurosciences, Boehringer Ingelheim, Acadia, Otsuka, Sunovion, and Lundbeck pharmaceutical companies. All other authors have no conflicts to report."

"Funding This work was supported by the National Institute of Mental Health Grants R21-MH112925, R21-MH122863, and R01-MH116039 to Dr. Strauss."